Verrica Pharmaceuticals
VRCA
51 hedge funds and large institutions have $150M invested in Verrica Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
46% more capital invested
Capital invested by funds: $103M → $150M (+$47.3M)
16% more funds holding
Funds holding: 44 → 51 (+7)
0.15% more ownership
Funds ownership: 3.46% → 3.61% (+0.15%)
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$6.28M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$2.77M |
| 3 |
PA
Perceptive Advisors
New York
|
+$2.77M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.59M |
| 5 |
JG
Jefferies Group
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.18M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$576K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$359K |
| 4 |
BlackRock
New York
|
-$244K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$230K |
VRCA Hedge Fund Activity: Q1 2021 in Review
51 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2021, worth a combined $150M — up 46% from $103M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VRCA positions and 2 closed out — a net gain of 7 holders — while 14 added to existing stakes and 19 trimmed.
The largest buyer was Altium Capital Management, adding an estimated $6.28M. The largest seller was Millennium Management, cutting an estimated $4.18M.
- 51 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2021, up from 44 in Q4 2020.
- Funds reported $150M of Verrica Pharmaceuticals stock for Q1 2021, up 46% quarter-over-quarter.
- 9 funds opened new Verrica Pharmaceuticals positions in Q1 2021 and 2 closed out, a net change of +7 holders.
- The largest Verrica Pharmaceuticals buyer in Q1 2021 was Altium Capital Management, an estimated $6.28M added.
- The largest Verrica Pharmaceuticals seller in Q1 2021 was Millennium Management, an estimated $4.18M sold.
Based on aggregated 13F filings for Q1 2021.